Mitazalimab is under clinical development by Alligator Bioscience and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Mitazalimab’s likelihood of approval (LoA) and phase transition for Kidney Cancer (Renal Cell Cancer) took place on 09 Sep 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 09 Sep 2021 decreased Mitazalimab’s Phase Transition Success Rate (PTSR) for Melanoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Mitazalimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Mitazalimab overview

Mitazalimab (ADC-1013) is under development for the treatment of advanced solid tumors like non-small cell lung cancer (NSCLC), metastatic pancreatic ductal adenocarcinoma, cutaneous melanoma, prostate cancer, renal cell cancer, metastatic cancer and bladder cancer. The drug candidate is administered intra-tumorally and through intravenous infusion. It acts by targeting CD40. It is a monospecific, IgG1 antibody. ADC-1013 is developed by using ALLIGATOR-13, a fully human antibody library, and FIND (Fragment INduced Diversity), an in vitro based antibody optimization technology. It is based on IMCAN concept. The drug candidate is a new molecular entity (NME).

Alligator Bioscience overview

Alligator Bioscience is a pharmaceuticals and healthcare company. The company’s pipeline products include ATOR-1015, ATOR-1017 and ALG.APV-527. The ADC-1013, is a human, monospecific, agonistic, IgG1 antibody used for immunotherapy of cancer; ATOR-1015, is a bispecific immune activating antibody intended for tumor-directed immunotherapy. Its preclinical development phase products ATOR-1017 and ALG.APV-527 are antibodies for activating the co-stimulatory receptor 4-1BB, and for treating tumor-directed immunotherapy respectively. The company develops immunotherapies such as agonistic mono- and bispecific antibodies. It develops immunotherapeutic product candidates using proprietary technologies, Alligator-Gold and fragment induced diversity (FIND). Alligator Bioscience is headquartered in Lund, Sweden.

Quick View Mitazalimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Mitazalimab
Administration Pathway
  • Intratumor
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Alligator Bioscience
  • Originator: Alligator Bioscience
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.